Survival by PML/RAR-α isoform type.

Probabilities of disease-free survival for newly diagnosed patients achieving clinical complete remission (A) and overall survival (B) in patients who expressed either the short or long transcript of PML/RAR-α are shown. Tick marks indicate the time of last follow-up. Patients with the short transcript had an inferior remission duration (P = .06) and overall survival (P = .08) compared with patients expressing the long isoform.